Holen Sie sich die Stockscreener-App
2.812
3.68%
0.092
Schlusskurs vom Vortag:
$2.72
Offen:
$2.88
24-Stunden-Volumen:
163.46K
Relative Volume:
0.64
Marktkapitalisierung:
$106.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.66M
KGV:
-2.96
EPS:
-0.95
Netto-Cashflow:
$-24.36M
1W Leistung:
-38.02%
1M Leistung:
-38.02%
6M Leistung:
-18.50%
1J Leistung:
+10.59%
1-Tages-Spanne:
$2.785
$2.90
1-Wochen-Bereich:
$2.655
$4.9883
52-Wochen-Spanne:
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
Firmenname
Genelux Corp
Sektor
Branche
Telefon
805-267-9889
Adresse
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Vergleichen Sie GNLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.81 | 103.50M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.00 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.42 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.45 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.41 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Lake Street | Buy |
| 2024-10-29 | Eingeleitet | Guggenheim | Buy |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-09-12 | Eingeleitet | Maxim Group | Buy |
| 2023-02-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Alle ansehen
Genelux Corp Aktie (GNLX) Neueste Nachrichten
Can Genelux Corporation stock sustain revenue growth2025 Earnings Surprises & AI Powered Trade Plan Recommendations - ulpravda.ru
Genelux Announces Underwritten Public Offering to Raise Capital - TipRanks
Genelux Corp Announces $20 Million Public Offering - TradingView — Track All Markets
Genelux Corporation announces pricing of $20.0 million underwritten public offering of common stock - MarketScreener
Genelux prices public offering of 6.67 million shares at $3 each - Investing.com Australia
Genelux prices public offering of 6.67 million shares at $3 each By Investing.com - Investing.com South Africa
Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock - Quiver Quantitative
Genelux stock falls after announcing proposed public offering By Investing.com - Investing.com Canada
Genelux stock falls after announcing proposed public offering - Investing.com
Genelux announces proposed public offering of common stock - Investing.com
Genelux Corporation Announces Proposed Public Offering of Common Stock - MarketScreener
Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan
Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - Nasdaq
Genelux data update indicates disease early control, says H.C. Wainwright - TipRanks
Genelux reports encouraging interim data for Olvi-Vec trials - MSN
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data By Investing.com - Investing.com South Africa
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data - Investing.com Canada
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer - TipRanks
Genelux reports interim data of systemic administration of Olvi-Vec - TipRanks
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials - TipRanks
Experimental treatment shrank lung tumors up to 85% in early trial - Stock Titan
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - Sahm
Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Genelux appoints Jason Litten as chief medical officer By Investing.com - Investing.com Nigeria
Genelux Appoints Veteran Oncologist Jason Litten as CMO - TipRanks
Genelux appoints Jason Litten as CMO - TipRanks
Genelux Corporation Announces Change of Chief Medical Officer - MarketScreener
Genelux appoints Jason Litten as chief medical officer - Investing.com India
Genelux Corporation Appoints Dr. Jason Litten as Chief Medical Officer to Advance Olvi-Vec Development - Quiver Quantitative
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - GlobeNewswire Inc.
GENELUX CORP : BENCHMARK CUTS TARGET PRICE TO $23 FROM $25 - 富途牛牛
How interest rate cuts could boost Genelux Corporation stockAnalyst Upgrades & AI Alerts You Can Actually Trust - Bollywood Helpline
Flputnam Investment Management Co. Raises Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux (NASDAQ:GNLX) Cut to Sell at Wall Street Zen - Defense World
Cappello, Genelux CTO, sells $14k in GNLX stock By Investing.com - Investing.com Nigeria
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 4,509 Shares - MarketBeat
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 12,673 Shares of Stock - MarketBeat
Genelux SVP, Yu Yong, sells shares worth $16k By Investing.com - Investing.com Australia
Genelux president sells $66k in GNLX stock By Investing.com - Investing.com Australia
Genelux SVP, Yu Yong, sells shares worth $16k - Investing.com
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
VP Yu Surrenders 4,192 Of Genelux Corp [GNLX] - TradingView — Track All Markets
Genelux reports Q3 EPS (21c), consensus (21c) - MSN
Lake Street Sticks to Their Buy Rating for Genelux Corp. (GNLX) - The Globe and Mail
Genelux price target raised to $20 from $10 at Maxim - MSN
Genelux (NASDAQ:GNLX) Director Sells $50,000.00 in Stock - MarketBeat
Genelux (GNLX) Stock Analysis Report | Financials & Insights - Benzinga
GENELUX Corp Director Thomas John Sells 10,000 Shares - TradingView
Dir Thomas Sells 10,000 ($50K) Of Genelux Corp [GNLX] - TradingView
Wall Street analysts’ outlook for Genelux Corp (GNLX) - Setenews
Finanzdaten der Genelux Corp-Aktie (GNLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):